Checkmate 9la trial12/17/2023 ![]() We observed a very early separation of the Kaplan-Meier curves and, as mentioned before, we did observe a consistent benefit in overall survival. With four months of further follow-up consolidation and improvement of overall survival was seen now corresponding to a hazard ratio of 0.65. The data monitoring committee confirmed superiority for the primary endpoint of overall survival in a pre-specified interim analysis corresponding to a hazard ratio of 0.69. The primary endpoint was overall survival and secondary endpoints which were tested hierarchically were response, progression free survival and efficacy correlated to the PD-L1 expression status. So the concept was the comparison between short chemotherapy, two cycles of chemotherapy, in combination with the immunotherapy combination of nivolumab and ipilimumab, compared to standard chemotherapy. The idea of the CheckMate 9LA was the control of the fast tumour progression by adding two cycles of chemotherapy to the immunotherapy combination and to build on the survival benefit which has been generated by the use of nivolumab and ipilimumab. We also have seen in the CheckMate-227 trial that this combination was associated with a survival benefit, in particular a long-term survival benefit, compared to chemotherapy independent from our biomarkers, PD-L1 expression status and tumour mutational burden. The background has been the observation that the immunotherapy combination of two different checkpoint inhibitors, the anti-PD1 inhibitor nivolumab and the anti-CTLA-4 inhibitor ipilimumab, has the ability to generate a long-term overall survival benefit in several tumours. It’s my pleasure to talk to you about the results and the background of the CheckMate 9LA, a new treatment opportunity for patients with metastatic non-small cell lung cancer. I’m working at the Lungenklinik in northern Germany, I’m specialised in thoracic oncology. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |